Key facts
- It has raised $13.7M; the latest was Seed Round ($13.7M) in Nov 2025.
- Notable investors include Parkwalk Advisors, Oxford Science Enterprises, AlbionVC, Apollo Health Ventures, Oxford University Innovation — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Scripta Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Scripta Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Scripta Therapeutics
Developer of therapeutic agents designed to modulate gene regulatory controllers in cells. The company's platform integrates genome-wide screening of transcription factor activity, computational modelling of gene regulatory networks, AI-driven identification of small molecule or biologic modulators, and cell-based functional assays, enabling the pharmaceutical and biotechnology sector to address underlying disease mechanisms, particularly in neurodegenerative or chronic conditions, to pursue disease-modifying treatments rather than only symptom-management approaches.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2024
- Employees
- 5
- Website
- scriptatherapeutics.com/
- Ownership
- Privately Held (backing)
Scripta Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Scripta Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Scripta Therapeutics in its N-PORT filings yet. We sweep new filings monthly.